• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过一种新颖的数学模拟方法揭示曲贝替定(ET-743)在核苷酸切除修复(NER)缺陷和NER正常细胞中对细胞周期阶段扰动的动力学。

Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.

作者信息

Tavecchio M, Natoli C, Ubezio P, Erba E, D'Incalci M

机构信息

Department of Oncology, Flow Cytometry Unit, Istituto di Richerche Farmacologiche Marco Negri, Milan, Italy.

出版信息

Cell Prolif. 2007 Dec;40(6):885-904. doi: 10.1111/j.1365-2184.2007.00469.x.

DOI:10.1111/j.1365-2184.2007.00469.x
PMID:18021177
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6760722/
Abstract

OBJECTIVES

Trabectedin (ET-743, Yondelis) is a natural marine product, with antitumour activity, currently in phase II/III clinical trials. Previous studies have shown that cells hypersensitive to ultraviolet (UV)-rays because of nucleotide excision repair (NER) deficiency, were resistant to trabectedin. The purpose of this study was to investigate whether this resistance was associated with different drug-induced cell cycle perturbations.

MATERIALS AND METHODS

An isogenic NER-proficient cellular system (CHO-AA8) and a NER-deficient one (CHO-UV-96), lacking functional ERCC-1, were studied. Flow cytometric assays showed progressive accumulation of cells in G2 + M phase in NER-proficient but not in NER-deficient cells. Applying a computer simulation method, we realized that the dynamics of the cell cycle perturbations in all phases were complex.

RESULTS

Cells exposed to trabectedin during G1 and G2 + M first experienced a G1 block, while those exposed in S phase were delayed in S and G2 + M phases but eventually divided. In the presence of functional NER, exit from the G1 block was faster; then, cells progressed slowly through S phase and were subsequently blocked in G2 + M phase. This G2 + M processing of trabectedin-induced damage in NER-proficient cells was unable to restore cell cycling, suggesting a difficulty in repairing the damage.

CONCLUSIONS

This might be due either to important damage left unrepaired by previous G1 repair, or that NER activity itself caused DNA damage, or both. We speculate that in UV-96 cells repair mechanisms other than NER are activated both in G1 and G2 + M phases.

摘要

目的

曲贝替定(ET - 743,商品名Yondelis)是一种具有抗肿瘤活性的天然海洋产物,目前正处于II/III期临床试验阶段。先前的研究表明,因核苷酸切除修复(NER)缺陷而对紫外线(UV)敏感的细胞对曲贝替定具有抗性。本研究的目的是调查这种抗性是否与不同药物诱导的细胞周期扰动有关。

材料与方法

研究了一个等基因的NER功能正常的细胞系(CHO - AA8)和一个NER功能缺陷的细胞系(CHO - UV - 96),后者缺乏功能性ERCC - 1。流式细胞术分析显示,NER功能正常的细胞中细胞在G2 + M期逐渐积累,而NER功能缺陷的细胞则不然。应用计算机模拟方法,我们认识到细胞周期各阶段扰动的动态过程是复杂的。

结果

在G1期和G2 + M期暴露于曲贝替定的细胞首先经历G1期阻滞,而在S期暴露的细胞在S期和G2 + M期延迟,但最终分裂。在存在功能性NER的情况下,从G1期阻滞中退出更快;然后细胞缓慢通过S期,随后被阻滞在G2 + M期。曲贝替定诱导NER功能正常的细胞损伤后的这种G2 + M期处理无法恢复细胞周期进程,提示损伤修复存在困难。

结论

这可能是由于先前G1期修复留下的未修复的重要损伤,或者NER活性本身导致了DNA损伤,或者两者皆有。我们推测在UV - 96细胞中,除NER之外的其他修复机制在G1期和G2 + M期均被激活。

相似文献

1
Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.通过一种新颖的数学模拟方法揭示曲贝替定(ET-743)在核苷酸切除修复(NER)缺陷和NER正常细胞中对细胞周期阶段扰动的动力学。
Cell Prolif. 2007 Dec;40(6):885-904. doi: 10.1111/j.1365-2184.2007.00469.x.
2
Role of homologous recombination in trabectedin-induced DNA damage.同源重组在曲贝替定诱导的DNA损伤中的作用。
Eur J Cancer. 2008 Mar;44(4):609-18. doi: 10.1016/j.ejca.2008.01.003. Epub 2008 Feb 19.
3
Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.抗肿瘤药物曲贝替定作用机制中核苷酸切除修复与同源重组DNA修复途径之间的相互作用
Cancer Res. 2006 Aug 15;66(16):8155-62. doi: 10.1158/0008-5472.CAN-06-0179.
4
Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.曲贝替定及其 C 亚基修饰类似物 PM01183 可减弱核苷酸切除修复,并对铂类耐药细胞有活性。
Mol Cancer Ther. 2011 Aug;10(8):1481-9. doi: 10.1158/1535-7163.MCT-11-0252. Epub 2011 May 27.
5
Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.对曲贝替定产生获得性耐药的癌细胞对铂类药物的敏感性增加。
Br J Cancer. 2015 Dec 22;113(12):1687-93. doi: 10.1038/bjc.2015.407. Epub 2015 Dec 3.
6
Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells.曲贝替定对前列腺癌干细胞的作用:增强G2/M期阻滞、诱导半胱天冬酶相关凋亡并降低E-钙黏蛋白依赖性细胞间黏附
PLoS One. 2015 Oct 20;10(10):e0141090. doi: 10.1371/journal.pone.0141090. eCollection 2015.
7
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.埃博霉素-743(ET-743),一种天然海洋化合物,具有独特的作用机制。
Eur J Cancer. 2001 Jan;37(1):97-105. doi: 10.1016/s0959-8049(00)00357-9.
8
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).比较 trabectedin、lurbinectedin(PM01183)和 Zalypsis®(PM00104)的体外和体内生物效应。
Int J Cancer. 2013 Nov;133(9):2024-33. doi: 10.1002/ijc.28213. Epub 2013 May 25.
9
Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.分析乳腺癌中与 DNA 修复相关的基因,揭示 CUL4A 泛素连接酶作为 trabectedin 反应的新型生物标志物。
Mol Cancer Ther. 2013 Apr;12(4):530-41. doi: 10.1158/1535-7163.MCT-12-0768. Epub 2013 Jan 30.
10
Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.响应曲贝替定,与希佩尔-林道综合征相关的及转录偶联核苷酸切除修复依赖性的RNA聚合酶II降解
Clin Cancer Res. 2008 Oct 15;14(20):6449-55. doi: 10.1158/1078-0432.CCR-08-0730.

引用本文的文献

1
Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.评估联合曲贝替定和低剂量放疗治疗转移性软组织肉瘤患者的安全性和疗效:一项非随机 1/2 期临床试验。
JAMA Oncol. 2020 Apr 1;6(4):535-541. doi: 10.1001/jamaoncol.2019.6584.
2
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.曲贝替定在骨髓增生异常/骨髓增殖性肿瘤中的抗肿瘤活性。
Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10.
3
Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.胰腺癌中厄洛替尼与吉西他滨序贯治疗反应的综合实验与模拟研究
Oncotarget. 2016 Mar 29;7(13):15492-506. doi: 10.18632/oncotarget.7491.
4
Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.对曲贝替定产生获得性耐药的癌细胞对铂类药物的敏感性增加。
Br J Cancer. 2015 Dec 22;113(12):1687-93. doi: 10.1038/bjc.2015.407. Epub 2015 Dec 3.
5
Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells.联合化疗效果的药效学模型预测吉西他滨和曲贝替定在胰腺癌细胞中的协同活性。
Cancer Chemother Pharmacol. 2016 Jan;77(1):181-93. doi: 10.1007/s00280-015-2907-4. Epub 2015 Nov 25.
6
Comparative analysis of multilineage properties of mesenchymal stromal cells derived from fetal sources shows an advantage of mesenchymal stromal cells isolated from cord blood in chondrogenic differentiation potential.对源自胎儿的间充质基质细胞的多谱系特性进行比较分析,结果显示从脐带血中分离出的间充质基质细胞在软骨形成分化潜能方面具有优势。
Cytotherapy. 2014 Jul;16(7):893-905. doi: 10.1016/j.jcyt.2014.02.008. Epub 2014 May 1.
7
Activity of trabectidin in desmoplastic small round cell tumor. trabectidin 在促结缔组织增生性小圆细胞肿瘤中的活性。
Med Oncol. 2011 Dec;28 Suppl 1:S644-6. doi: 10.1007/s12032-010-9687-9. Epub 2010 Oct 7.

本文引用的文献

1
Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.抗肿瘤药物曲贝替定作用机制中核苷酸切除修复与同源重组DNA修复途径之间的相互作用
Cancer Res. 2006 Aug 15;66(16):8155-62. doi: 10.1158/0008-5472.CAN-06-0179.
2
A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.一项关于Yondelis(曲贝替定,ET-743)作为24小时持续静脉输注用于经治晚期乳腺癌的II期研究。
Br J Cancer. 2006 Jun 5;94(11):1610-4. doi: 10.1038/sj.bjc.6603142.
3
Interpreting cell cycle effects of drugs: the case of melphalan.解读药物对细胞周期的影响:美法仑的案例
Cancer Chemother Pharmacol. 2006 Apr;57(4):443-57. doi: 10.1007/s00280-005-0044-1. Epub 2005 Sep 30.
4
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.对于铂类和紫杉烷类治疗失败后的卵巢癌女性患者,使用曲贝替定治疗。
J Clin Oncol. 2005 Mar 20;23(9):1867-74. doi: 10.1200/JCO.2005.09.032.
5
The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.海洋产品Yondelis(ET - 743,曲贝替定)的独特生物学特性与其类似物ET - 637相同,后者缺少C环。
Oncol Res. 2004;14(11-12):579-87. doi: 10.3727/0965040042707925.
6
Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach.通过一种新型数学模拟方法解析拓扑替康的细胞生长抑制和细胞毒性作用。
Cancer Res. 2004 Apr 15;64(8):2825-32. doi: 10.1158/0008-5472.can-03-3810.
7
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.埃博霉素743在化疗难治性进展期软组织肉瘤患者中的II期及药代动力学研究。
J Clin Oncol. 2004 Apr 15;22(8):1480-90. doi: 10.1200/JCO.2004.02.098.
8
Regulation and mechanisms of mammalian double-strand break repair.哺乳动物双链断裂修复的调控与机制
Oncogene. 2003 Sep 1;22(37):5792-812. doi: 10.1038/sj.onc.1206679.
9
DNA damage and repair.DNA损伤与修复
Nature. 2003 Jan 23;421(6921):436-40. doi: 10.1038/nature01408.
10
Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.基于抗肿瘤活性和基因表达的海鞘素Et 743和邻苯海鞘素Pt 650分析
Chem Biol. 2001 Dec;8(12):1151-60. doi: 10.1016/s1074-5521(01)00082-5.